| |
| |
|
| Insider
Information: |
Foehr Matthew W |
| Relationship: |
President and CEO, Dir... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
3,948,737 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$33,186,682 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,948,737 |
|
|
| Total
Value |
$33,186,682 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
6
|
0
|
| Stock
price went down : |
7
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
 32.7%
|
 -89.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
162,187 |
2011-04-18 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2022-05-02 |
111,250 |
2015-05-04 |
0 |
Premium* |
|
|
Qualigen Therapeutics Inc |
QLGN |
Director |
2020-04-10 |
138,635 |
2015-06-24 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
President and CEO, Dir... |
2024-05-24 |
3,536,665 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
136 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-08-21 |
4 |
OE |
$14.47 |
$163,338 |
D/D |
8,015 |
162,638 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-08-21 |
4 |
AS |
$112.88 |
$815,541 |
D/D |
(7,225) |
155,413 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-08-24 |
4 |
AS |
$110.89 |
$8,649 |
D/D |
(78) |
155,413 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-08-24 |
4 |
OE |
$21.92 |
$1,710 |
D/D |
78 |
155,491 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-01-25 |
4 |
D |
$156.01 |
$518,733 |
D/D |
(3,325) |
160,603 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,515 |
162,875 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,595 |
167,198 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-02-04 |
4 |
S |
$176.86 |
$7,878,582 |
D/D |
(44,547) |
168,198 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-02-04 |
4 |
OE |
$21.92 |
$1,050,890 |
D/D |
45,547 |
212,745 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-02-15 |
4 |
D |
$172.46 |
$534,281 |
D/D |
(3,098) |
165,100 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-05-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,500 |
162,600 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-05-28 |
4 |
OE |
$56.26 |
$98,736 |
D/D |
1,755 |
164,355 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-08-04 |
4 |
OE |
$21.92 |
$291,745 |
D/D |
9,982 |
165,497 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-08-04 |
4 |
S |
$109.67 |
$969,507 |
D/D |
(8,840) |
164,355 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-11-11 |
4 |
OE |
$21.92 |
$347,818 |
D/D |
12,188 |
177,685 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-11-11 |
4 |
S |
$163.02 |
$1,819,255 |
D/D |
(11,160) |
166,525 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2022-01-26 |
4 |
D |
$113.68 |
$582,610 |
D/D |
(5,125) |
174,400 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
179,525 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2022-02-15 |
4 |
D |
$123.68 |
$438,569 |
D/D |
(3,546) |
170,854 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2022-05-13 |
4 |
B |
$82.76 |
$206,910 |
D/D |
2,500 |
173,354 |
2.74 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Former Executive Officer |
– – – |
2022-11-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(20,304) |
162,187 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2022-11-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
1,431,618 |
3,296,665 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President & CEO |
• • – |
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,305,350 |
1,305,350 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President & CEO |
• • – |
2022-11-09 |
4 |
B |
$2.76 |
$276,160 |
D/D |
100,000 |
1,405,350 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President & CEO |
• • – |
2022-11-30 |
4 |
B |
$3.39 |
$1,016,340 |
D/D |
300,000 |
1,705,350 |
2.81 |
% |
|
136 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
